FEATURES OF THERAPEUTIC TACTICS FOR HERPES TREATMENT CONSIDERING THE PATIENT'S IMMUNE PROFILE
DOI: 10.22138/2500-0918-2026-23-2-232-240
E.A. Levkova¹, E.A. Skvortsova², S.Yu. Terentyev²,
V.V. Dmitrieva¹, A.A. Buchka¹
¹ Peoples' Friendship University of Russia (RUDN University), Department of Immunology, Moscow, Russian Federation;
² Polyclinic No. 1 of the Ministry of Science and Higher Education of the Russian Federation,
Moscow, Russian Federation
Abstract. This article presents factual data on the specifics of therapeutic tactics in patients with chronic, recurrent herpesvirus infection. Objective: To determine the specifics of therapeutic tactics for treating herpesvirus infection depending on the patient's immune profile. Materials and Methods. The study included 320 patients: 215 women and 105 men. The age of the subjects was 41.2 ± 0.94 years. The annual exacerbation rate was 6.17 ± 0.42. All patients were HIV-negative. The somatic burden index was 2.8 ± 0.29. Venous (including heparinized) blood served as the study material. Cellular analysis was performed using monoclonal antibodies on a flow cytometer (CD3+, CD4+, CD8+, CD16+56+, CD20+, CD25+). Immunoglobulins were determined by turbidimetry (IgG, IgA, IgM, IgE). Interferons α and γ (spontaneous and induced) were determined by ELISA. Virological testing included PCR assessment of HSV 1/2 contamination, taking into account quantitative criteria and the distribution of localizations. Calculations were performed on a Samsung SyncMaster 755DFX PC using Excel 7.0. Differences in mean values were considered significant at P<0.05. Modern statistical analysis methods, such as Multiple Regression, were applied to all studied parameters during the study. Research Results. Thus, taking into account the immunological profile in clinical practice for recurrent herpes allows for a shift from «uniform antiviral drug prescription» to personalized strategies. The more pronounced the signs of immune dysregulation (decreased IRI, decreased NK cells, decreased IgM, and impaired interferon response), the higher the likelihood of insufficient efficacy of episodic treatment alone, and the more justified is a suppressive regimen with an expanded immunological assessment and correction of underlying factors.
Keywords: herpes, immune system, gender differences, interferons, antibodies, treatment, vaccination
There is no conflict of interest.
Contact details of the corresponding author:
Levkova Elena A.
elenaalevkova@gmail.com
Received: 03.02.2026
For citation: Levkova E.A., Skvortsova E.A., Terentyev S.Yu., Dmitrieva V.V., Buchka A.A. Features of therapeutic tactics for herpes treatment considering the patient's immune profile [Online] Vestn. Ural. Med. Akad. Nauki. = Journal of Ural Medical Academic Science. 2026, Vol. 23, no. 2, pp. 232–240. DOI: 10.22138/2500-0918-2026-23-2-232-240 (In Russ)
References
1. World Health Organization. Herpes simplex virus (Fact sheet), 30 May 2025.
2. James C, Harfouche M, Welton NJ, Turner KM, Abu-Raddad LJ, Gottlieb SL, Looker KJ. Herpes simplex virus: global infection prevalence and incidence estimates, 2016. Bull World Health Organ. 2020 May 1;98 (5):315-329.
3. https://www.researchgate.net/publication/357782324_2021_CDC_Update_Treatment_and_Complications_of_Sexually_Transmitted_Infections_STIs
4. Gupta R., Warren T., Wald A. Genital herpes. The Lancet. 2007;370:2127–2137.
5. Groves M.J.O. Genital Herpes: A Review. American Family Physician. 2016;93(11):928–934.
6. Workowski K.A., Bachmann L.H., Chan P.A., et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep. 2021;70(4):1–187.
7. Ashley R.L., Wald A. Genital herpes: review of the epidemic and potential use of type-specific serology. Clin Microbiol Rev. 1999;12(1):1–8.
8. Mindel A. Genital herpes—how much of a public-health problem? The Lancet. 1998;351(Suppl 3):SIII16.
9. Kimberlin D.W. Herpes simplex virus infections of the newborn. Clin Perinatol. 2007.
10. Pinninti S.G., Kimberlin D.W. Neonatal herpes simplex virus infections. Pediatr Clin North Am. 2013;60(2):351–365.
Authors
Levkova Elena A.
Doctor of Medical Sciences, Professor, Professor of the Department
Peoples' Friendship University of Russia (RUDN University), Department of Immunology, Moscow, Russian Federation
117198, Moscow, Miklukho-Maklaya St., 6
elenaalevkova@gmail.com
Skvortsova Elena A.
Head of the Clinical Diagnostic Laboratory
Polyclinic No. 1 of the Ministry of Education and Science of the Russian Federation, Moscow, Russian Federation
101000, Moscow, Sretensky Boulevard, Building 6/1, Bldg. 2
elenaalevkova@gmail.com
Terentyev Sergey Y.
Candidate of Medical Sciences, Head of the Clinical and Diagnostic Department
Polyclinic No. 1 of the Ministry of Education and Science of the Russian Federation, Moscow, Russian Federation
101000, Moscow, Sretensky Boulevard, Building 6/1, Bldg. 2
terentyev@poliran.ru
Dmitrieva Victoria V.
5th-year student, Faculty of General Medicine, RUDN University Institute of Medicine
Peoples' Friendship University of Russia (RUDN University), Department of Immunology, Moscow, Russian Federation
117198, Moscow, Miklukho-Maklaya St., 6
1032212882@pfur.ru
Buchka Anastasia A.
resident of the Department of Immunology
Peoples' Friendship University of Russia (RUDN), Department of Immunology, Moscow, Russian Federation
117198, Moscow, Miklukho-Maklaya St., 6
artem_buchka@rgs.ru.